Showing 3141-3150 of 4166 results for "".
- Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitishttps://modernod.com/news/clearside-biomedical-to-present-pivotal-phase-3-peachtree-clinical-trial-in-macular-edema-associated-with-non-infectious-uveitis/2479896/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreo
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi
- ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/thrombogenics-enrolls-first-patient-in-phase-1-clinical-study-evaluating-thr-149-for-treatment-of-dme/2480139/ThromboGenics NV announced that it has successfully enrolled the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898). THR-149 is a novel plasma kallikrein inhibitor generated using Bicycle Therapeu
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH
- Eyedaptic Unveils EYE7 Smart Glasseshttps://modernod.com/news/eyedaptic-unveils-eye7-smart-glasses/2486374/Key Takeaways Eyedaptic has launched the EYE7 smart glasses with integrated AI visual assistants. The EYE7 reportedly provides lightweight comfort, personalized visual modes, and enhanced acuity/contrast for users with vision impairments. The Eyedap
- NextGen Healthcare Expands Eye Care Solutions Through Strategic Alignment with Eyefinityhttps://modernod.com/news/nextgen-healthcare-expands-eye-care-solutions-through-strategic-alignment-with-eyefinity/2484213/NextGen Healthcare said it is enhancing its suite of offerings for optometrists and ophthalmologists through a new alignment with Eyefinity, a VSP Vision company. According to NextGen, the new collaboration will d
- American Academy of Optometry Announces 2025 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2025-award-recipients/2484131/Each year, the American Academy of Optometry (AAOpt) recognizes distinguished individuals whose contributions advance the profession of optometry and vision science. The Academy’s awardees are nominated by fellows and are based on contributions made in t
- LKC Technologies: RETeval DR Score Superior in Predicting Diabetic Retinopathy Outcomeshttps://modernod.com/news/lkc-technologies-reteval-dr-score-superior-in-predicting-diabetic-retinopathy-outcomes/2482924/LKC Technologies, a provider of electroretinography (ERG)-based functional diagnostics, announced the publication of a study that found that ERG/pupillometry outperforms structural imaging in identifying patients at highest risk of progressing to vision-t
- Boehringer Ingelheim and Re-Vana Therapeutics Collaborate to Develop Long-Acting Ophthalmic Therapieshttps://modernod.com/news/boehringer-ingelheim-and-re-vana-therapeutics-announce-collaboration-to-develop-long-acting-ophthalmic-therapies/2482905/Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement designed to accelerate the development of first-in-class extended-release therapies for vision-threatening eye diseases.
- NIH Researchers Identify Brain Circuits Responsible for Visual Acuityhttps://modernod.com/news/nih-researchers-identify-brain-circuits-responsible-for-visual-acuity/2482836/Researchers at the National Institutes of Health (NIH) says they have identified specific brain circuits vital to visual acuity and uncovered how these circuits are disrupted by damage to retinal cells, a discovery that could reshape the future of vision resto